Analyst Research

Report Title Price
Provider: MacroRisk Analytics/EconomicInvestor
Provider: Pechala's Reports
Provider: Pechala's Reports
Provider: Reuters Investment Profile

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Skystar Bio Pharmaceutical Co Reaffirms FY 2013 Revenue Guidance

Friday, 15 Nov 2013 05:00am EST 

Skystar Bio-Pharmaceutical Company reiterated fiscal 2013 revenue guidance to be in the range of $40 million to $45 million. 

Company Quote

-0.1 -2.18%
26 Dec 2014